Goldman Sachs’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-166,300
| Closed | -$13.2M | – | 6736 |
|
|
2025
Q4 | $13.2M | Hold |
166,300
| – | – | ﹤0.01% | 2806 |
|
|
2025
Q3 | $10.9M | Buy |
+166,300
| New | +$8.12M | ﹤0.01% | 2875 |
|
|
2025
Q1 | – | Sell |
-50,000
| Closed | -$1.75M | – | 6235 |
|
|
2024
Q4 | $1.75M | Hold |
50,000
| – | – | ﹤0.01% | 4397 |
|
|
2024
Q3 | $2M | Buy |
50,000
+6,500
| +15% | +$302K | ﹤0.01% | 4153 |
|
|
2024
Q2 | $2.07M | Buy |
43,500
+31,500
| +263% | +$1.29M | ﹤0.01% | 3891 |
|
|
2024
Q1 | $520K | Sell |
12,000
-18,000
| -60% | -$858K | ﹤0.01% | 4729 |
|
|
2023
Q4 | $1.52M | Buy |
30,000
+21,100
| +237% | +$1.01M | ﹤0.01% | 4130 |
|
|
2023
Q3 | $404K | Buy |
+8,900
| New | +$367K | ﹤0.01% | 4749 |
|
|
2023
Q1 | – | Sell |
-25,000
| Closed | -$944K | – | 6075 |
|
|
2022
Q4 | $944K | Buy |
+25,000
| New | +$1.05M | ﹤0.01% | 4462 |
|
|
2020
Q2 | – | Sell |
-20,000
| Closed | -$946K | – | 5341 |
|
|
2020
Q1 | $946K | Buy |
+20,000
| New | +$1.11M | ﹤0.01% | 3804 |
|
|
2018
Q4 | – | Sell |
-45,700
| Closed | -$2.36M | – | 5453 |
|
|
2018
Q3 | $2.36M | Buy |
+45,700
| New | +$2.15M | ﹤0.01% | 3485 |
|
|
2018
Q1 | – | Sell |
-29,100
| Closed | -$1.46M | – | 6132 |
|
|
2017
Q4 | $1.46M | Sell |
29,100
-8,600
| -23% | -$472K | ﹤0.01% | 4034 |
|
|
2017
Q3 | $1.91M | Hold |
37,700
| – | – | ﹤0.01% | 4039 |
|
|
2017
Q2 | $1.92M | Buy |
+37,700
| New | +$1.76M | ﹤0.01% | 3875 |
|
|
2016
Q3 | – | Sell |
-206,800
| Closed | -$4.82M | – | 7091 |
|
|
2016
Q2 | $4.82M | Buy |
206,800
+141,800
| +218% | +$4.57M | ﹤0.01% | 2903 |
|
|
2016
Q1 | $2.63M | Sell |
65,000
-70,000
| -52% | -$2.84M | ﹤0.01% | 3233 |
|
|
2015
Q4 | $8.36M | Buy |
135,000
+27,700
| +26% | +$1.49M | ﹤0.01% | 2392 |
|
|
2015
Q3 | $4.34M | Sell |
107,300
-84,800
| -44% | -$4.39M | ﹤0.01% | 3006 |
|
|
2015
Q2 | $11.1M | Buy |
192,100
+87,400
| +83% | +$5.56M | ﹤0.01% | 2256 |
|
|
2015
Q1 | $6.67M | Sell |
104,700
-240,000
| -70% | -$16.3M | ﹤0.01% | 2629 |
|
|
2014
Q4 | $21.3M | Sell |
344,700
-25,300
| -7% | -$1.25M | 0.01% | 1777 |
|
|
2014
Q3 | $14.4M | Sell |
370,000
-76,800
| -17% | -$2.72M | ﹤0.01% | 2058 |
|
|
2014
Q2 | $15.4M | Buy |
446,800
+23,400
| +6% | +$737K | ﹤0.01% | 2007 |
|
|
2014
Q1 | $18.3M | Buy |
423,400
+373,400
| +747% | +$18.1M | 0.01% | 1839 |
|
|
2013
Q4 | $1.99M | Sell |
50,000
-75,000
| -60% | -$2.67M | ﹤0.01% | 4065 |
|
|
2013
Q3 | $4.69M | Buy |
125,000
+50,000
| +67% | +$1.49M | ﹤0.01% | 2998 |
|
|
2013
Q2 | $2.02M | Buy |
+75,000
| New | +$1.59M | ﹤0.01% | 3728 |
|
Other funds holding IONS
VPM
VCM
Goldman Sachs's IONS Position: Q1 2026 in Review
Goldman Sachs increased its Ionis Pharmaceuticals (IONS) stake by 99% in Q1 2026, buying an estimated $66.6M and bringing the position to 1,699,847 shares worth $128M. The position accounts for 0.01% of the portfolio, ranked #893.
Goldman Sachs first reported a position in IONS in Q2 2013 and has held it in 52 quarters since. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- Goldman Sachs held 1,699,847 shares of Ionis Pharmaceuticals worth $128M as of Q1 2026.
- Goldman Sachs bought 843,881 Ionis Pharmaceuticals shares in Q1 2026, an estimated $66.6M.
- Ionis Pharmaceuticals made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #893 holding.
- Goldman Sachs first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.